Table 2 Incremental cost-effectiveness ratio of EVAR for patients operated on for pancreas cancer.
| AAA size | Stage of pancreas cancer | |||||
|---|---|---|---|---|---|---|
| I | II | III | IVa | IVb | ||
| Median LY* | 6.34 | 3.60 | 2.56 | 1.08 | 0.59 | |
| Expected LY* | 6.34 | 5.40 | 3.07 | 2.06 | 1.61 | |
| ICER# | 5.0–5.9 cm | 3.59 | 4.48 | 24.00 | 127.10 | 198.43 |
| 6.0–6.9 cm | 2.14 | 2.43 | 8.73 | 25.68 | 47.13 | |
| ≧7 cm | 1.20 | 1.34 | 4.11 | 8.98 | 14.19 | |
*life years, #incremental cost-effectiveness ratio (million yen/QALY)